Immune Checkpoint Inhibitor Myocarditis and Myotoxicity. (PubMed, Circulation) - Sep 9, 2026 - "Corticosteroids are generally recommended; however, severe, progressive, or refractory disease increasingly supports pathophysiology-directed-based therapies, including abatacept and ruxolitinib. Evidence is promising for these therapies but not definitive, pending prospective trials. Rechallenge is often avoided but could be reassessed in selected patients under strict surveillance."
Checkpoint inhibition • IO biomarker • Journal • Review • Cardiovascular • CNS Disorders • Gastrointestinal Disorder • Immunology • Inflammation • Myositis • Oncology • Solid Tumor • Thymoma • Thymus Cancer • CD80
|